Question 1

What is LANADELUMAB-FLYO used for?

Accepted Answer

LANADELUMAB-FLYO (brand name TAKHZYRO) is a Other indicated for See full prescribing information.

Question 2

How does LANADELUMAB-FLYO work?

Accepted Answer

LANADELUMAB-FLYO works through the following mechanism: 12.1 Mechanism of Action Lanadelumab-flyo is a fully human monoclonal antibody (IgG1/κ-light chain) that binds plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with HAE. In patients with HAE due to C1-inhibitor (C1-INH) deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and results in angioedema attacks. Lanadelumab-flyo decreases plasma kallikrein activity to control excess bradykinin generation in patients with HAE..

Question 3

What are the most common side effects of LANADELUMAB-FLYO?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for LANADELUMAB-FLYO. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is LANADELUMAB-FLYO the same as TAKHZYRO?

Accepted Answer

TAKHZYRO is a brand name for LANADELUMAB-FLYO. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

LANADELUMAB-FLYO

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations